Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Accured (2022 - 2025)

Crinetics Pharmaceuticals (CRNX) has 4 years of Receivables - Accured data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Receivables - Accured fell 6.02% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, down 6.02%, while the annual FY2025 figure was $7.8 million, 6.02% down from the prior year.
  • Receivables - Accured reached $7.8 million in Q4 2025 per CRNX's latest filing, up from $6.3 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $8.4 million in Q2 2025 and bottomed at $1.4 million in Q4 2022.
  • Average Receivables - Accured over 4 years is $6.1 million, with a median of $7.2 million recorded in 2025.
  • Peak YoY movement for Receivables - Accured: soared 167.74% in 2024, then dropped 6.02% in 2025.
  • A 4-year view of Receivables - Accured shows it stood at $1.4 million in 2022, then soared by 121.43% to $3.1 million in 2023, then skyrocketed by 167.74% to $8.3 million in 2024, then dropped by 6.02% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Accured were $7.8 million in Q4 2025, $6.3 million in Q3 2025, and $8.4 million in Q2 2025.